An estimated 235,760 new cases of lung cancer are reported in the United States annually, and 131,880 people die of the disease. Approximately 84% of cases are classified as non-small cell lung cancer (NSCLC) (ACS, 2021). The most frequent genomic aberration among patients with NSCLC is the epidermal growth factor receptor (EGFR) mutation, approximately 2%-10% of which are exon 20 insertion mutations (Kumari et al, 2019; Dersarkissian et al, 2019). Exon 20 insertion mutations are a heterogenous group frequently associated with resistance to first- and second-line EGFR tyrosine kinase inhibitor (TKI) therapy (NCCN, 2021). Currently, there are no approved therapies specifically designed to treat EGFR exon 20 insertion–mutant NSCLC (LCRF, 2020). There is an unmet need to develop effective targeted therapies to improve outcomes and quality of life in patients with this disease.